Ascelia Pharma AB (DE:7ZA)
FRANKFURT:7ZA
Want to see DE:7ZA full AI Analyst Report?
7ZA Stock Chart & Stats
€0.29
>-€0.01(-1.21%)
At close: 4:00 PM EST
€0.29
>-€0.01(-1.21%)
Day’s Range― - ―
52-Week Range€0.17 - €0.47
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€35.12M
Enterprise Value€324.10M
Total Cash (Recent Filing)€49.86M
Total Debt (Recent Filing)€970.00K
Price to Earnings (P/E)―
Beta1.34
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding126,868,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€8.11M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt (debt-to-equity ~0.01 in 2025) reduces fixed financing costs and interest burden, giving management flexibility to prioritize R&D and clinical milestones. Over 2–6 months this lowers insolvency risk and eases strategic options like partnerships or staged financings.
Improving Cash Burn TrendMaterial reduction in operating cash burn from 2022–2023 to 2025 indicates cost discipline or program reprioritization. Sustained lower burn extends runway, reduces near-term financing frequency, and materially de-risks execution of late-stage development over the coming months.
Focused Lead AssetA clear single focus on Orviglance targets a defined unmet need—MRI liver imaging for patients unsuitable for gadolinium. A differentiated, niche diagnostic product can simplify regulatory and commercial strategy and concentrate limited resources for a higher-probability outcome over the medium term.
Bears Say
Pre-Revenue ProfileBeing pre-revenue with no top-line means the business must rely on external capital, not operating cash, to fund development. Over 2–6 months this structural absence of revenue maintains dilution risk, limits internal reinvestment, and keeps commercial validation distant.
Persistent Negative Cash FlowConsistent negative operating and free cash flow (-72.3M in 2025) means the company continues to consume capital to progress trials. This structural cash burn necessitates continued fundraising or partnerships, exposing shareholders to dilution and execution risk over the medium term.
Eroding Equity BaseSteady decline in equity from 307.8M to 99.5M reflects cumulative losses and capital consumption. A weakened equity base reduces financial cushioning, limits borrowing capacity and bargaining power in raises or deals, heightening structural financing and dilution risk in the coming months.
Ascelia Pharma AB News
7ZA FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was €0.17 and its highest was €0.47 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is €35.12M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is May 12, 2026 which is in 11 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on Feb 05, 2026. The company reported -€0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.012.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 126,868,800 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -€0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -35.075%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in DE:7ZA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―